The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab.

ABSTRACT:

Purpose

Bevacizumab has evolved as an integral treatment option for patients with high-grade gliomas. Little is known about clinical risk factors that predispose patients with high-grade gliomas receiving bevacizumab to VTE or ICH. We sought to characterize the clinical risk factors associated with risk of either event.

Methods

In this multi-institutional retrospective study, we first evaluated patients with high-grade gliomas who were treated with bevacizumab at University of Texas MD Anderson Cancer Center from 2015-2021. We compared clinical and treatment-related factors among three cohorts: those who developed VTE, ICH, or neither. We further compared survival outcomes of these patients from the time of bevacizumab initiation. Then to further confirm our results in a non

SUBMITTER: Dasgupta P 

PROVIDER: S-EPMC11758674 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature